It works18 May 2024 10:41
Ignore the tedious repetitive clickbait spam, unless you want to buy a 3D T-shirt of a parrot. The science has been clearly presented by CC. It’s about the platform, they’re taking their time to learn as much as possible. It delivers the drug to the tumour at a ratio of 100:1, works for mid and high fap, reducing side effects and enabling optimisation, different dosage regimes that can achieve the holy grail - all aligned with the FDAs preferred approach.
The SP disconnect is thanks to Alan and Tony and due to the funding sh.t show that is the cesspit of AIM, if they’d raised at a premium we wouldn’t be here on fundamentals. Value will out, only question mark is what happens to Dx and if that will plug the funding gap to see AVA6k through P2 to market. We’ll hopefully hear more from CC on strategy at the AGM.